Loading
institutionsInstitution
Huntsman Cancer Institute, University of Utah
The Mountain West's NCI comprehensive centre, built on Utah's genealogy-linked population database that helped find BRCA1 and other hereditary cancer genes.
Also called: HCI
Overview
Founded by Jon Huntsman and NCI-designated in 1999 (comprehensive since 2015), Huntsman Cancer Institute serves Utah, Idaho, Montana, Nevada and Wyoming. The Utah Population Database, which links genealogies to medical records, enabled the cloning of BRCA1 by Mark Skolnick's group in 1994 and discoveries in familial colorectal cancer and melanoma, and remains a unique resource for hereditary cancer research. Neeraj Agarwal leads major prostate cancer trials, including TALAPRO-2 (talazoparib plus enzalutamide), and the institute operates its own cancer hospital with inpatient and outpatient care. Mary Beckerle is its long-time CEO.
Location
Salt Lake City, UT, US
Type
cancer center · University of Utah
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#77 · 43 points (0 Newsweek + 15 NCI + 28 from 14 linked objects) · ranking
- Hereditary cancer (Utah Population Database)
- Prostate cancer trials
- Melanoma
Bradley Cairns
Chief Executive Officer
Chromatin and epigeneticsGermline biologyCancer research leadership
Epigenetics researcher who became CEO of Huntsman Cancer Institute at the University of Utah in September 2025.
Jon M. Huntsman Sr.
Cancer survivor who founded and funded Huntsman Cancer Institute
Cancer centre buildingHereditary cancer researchPatient care
A chemicals billionaire treated for cancer several times, he and his wife Karen founded Huntsman Cancer Institute in 1995 and their family gave more than $400 million to build its research institute and hospital.
Neeraj Agarwal
SWOG Executive Officer, Genitourinary and Early Therapeutics; Professor of Medicine, Huntsman Cancer Institute, University of Utah
Prostate cancerKidney cancerTargeted therapy
GU oncologist who led TALAPRO-2 and other trials combining PARP inhibitors with hormone therapy.
Similar pages
- TrialTALAPRO-2
Shares Neeraj Agarwal, Talazoparib, Enzalutamide, PARP inhibitors.
- PersonJennifer K. Litton
Shares Talazoparib, PARP inhibitors, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing.
- Key paperManagement of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline
Shares Talazoparib, Inherited risk is mostly unidentified, PARP inhibitors, BRCA1 / BRCA2 (HRD).
- TrialStudy of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Shares Talazoparib, Enzalutamide, PARP inhibitors, Prostate cancer.
- Key paperThe risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, National Cancer Institute (NIH).
- InstitutionThe University of Kansas Cancer Center
Shares SWOG Cancer Research Network, Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, National Cancer Institute (NIH).
- TermWho is eligible for a PARP inhibitor in prostate cancer, and why the gene matters
Shares Talazoparib, PARP inhibitors, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing.
- InstitutionInstituto Português de Oncologia do Porto Francisco Gentil
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Prostate cancer.
cancers
technologies
targets
drugs
ApprovedSmall-molecule AR antagonist
Enzalutamide · Xtandi
ApprovedSmall-molecule PARP inhibitor
Talazoparib · Talzenna